Post-approval trial to evaluate the performance of the 10F-Reitan Catheter Pump in advanced heart failure patients
Organizational Data
- DRKS-ID:
- DRKS00013205
- Recruitment Status:
- Recruiting ongoing
- Date of registration in DRKS:
- 2019-04-01
- Last update in DRKS:
- 2020-04-22
- Registration type:
- Prospective
Acronym/abbreviation of the study
RCPerformance
URL of the study
No Entry
Brief summary in lay language
Evaluation of the 10F-RCP of heart failure patients with impaired kidney function.
Brief summary in scientific language
Heart failure is a wide-spread condition and a severe disease with high mortality. According to American authorities there are 5.7 million Americans with heart failure. Once the diagnosis heart failure is established, 50% of patients will die within 5 years. The severity of the disease is also described by the NYHA class and in NYHA-class III (moderate symptoms) one year mortality is estimated at 10-15% and in NYHA-class IV (severe symptoms) at 30-40%. (Reisfield GM) Beside heart failure is life threatening it also costs economies a lot of money (e.g. $30.7 billion p.a. for the USA). Most patients will therefore be on heavy medication. Despite the use of modern drugs many patients will experience a failing clinical condition with development of intractable heart failure. Because of the failing heart the organs will not be sufficiently supplied with blood and end-organ failure will occur. It is common to observe this as renal failure both because the function of the kidneys are pressure dependent, but also because some of the drugs used in the treatment of heart failure may exert a direct negative influence on the renal function. It is also common to observe a reduced liver function with increasing liver enzymes and attenuated production of coagulation factors. Some patients will experience episodes of acute decompensation with need of hospitalization and intensified medical treatment or even some kind of mechanical circulatory support. The objective of this trial is to demonstrate that the 10F-RCP is safe and effective when used as short-term percutaneous circulatory support system in a real life end stage heart failure population with acute decompensation. The trial aims to confirm the hypothesis that the 10F-RCP improves organ perfusion (especially the kidneys) if compromised due to low perfusion pressure.
Health condition or problem studied
- Free text:
- acute decompensated heart failure (ADHF), cardiorenal syndrome (CRS)
- ICD10:
- I50.9 - Heart failure, unspecified
- ICD10:
- I42.0 - Dilated cardiomyopathy
- ICD10:
- I11 - Hypertensive heart disease
- ICD10:
- I25 - Chronic ischaemic heart disease
- Healthy volunteers:
- No Entry
Interventions, Observational Groups
- Arm 1:
- Acute Decompensated Heart Failure (ADHF) patients with impaired kidney function will be treated für 24 hours with the 10F-Reitan Catherer Pump (10F-RCP). The 10F-RCP is percutaneous mechanical circulatory support (pMCS).
Endpoints
- Primary outcome:
- Improvement in eGFR (based on MDRD formula) during 24 hours (Day 1) treatment with the 10F-RCP compared to baseline
- Secondary outcome:
- 10F-RCP treatment induced changes in the following parameters: PCWP, CVP, PAP, MAP, CI, CO after a treatment duration of 24h compared to baseline data; 10F-RCP treatment induced changes in the following parameters: eGFR, SCr, Cystatin C, NT-proBNP during treatment (Day 1) and after treatment at Day 2, Day 3, Day 5 and Day 7 (or earlier if patient will be discharged or switched to another device therapy) compared to baseline data; 10F-RCP treatment induced changes in the following parameters: Lactate, AST/ALT, Troponine T, CKMB, CK, Myoglobine, LDH, Fibrinogene, and Urine Output during treatment (Day 1) and after treatment and additionally at Day 2 for Lactate and LDH. INTERMACS level changes at baseline compared to 24 hours of treatment (Day 1), Day 2 and Day 7* (or earlier if patient will be discharged or switched to another device therapy); Adverse Events (as risk-assessment): Major Bleeding; Hemolysis; Device Malfunction; Limb ischemia; Need for transfusion; thrombo-embolic complication; Neurologic complication.
Study Design
- Purpose:
- Treatment
- Retrospective/prospective:
- No Entry
- Study type:
- Non-interventional
- Longitudinal/cross-sectional:
- No Entry
- Study type non-interventional:
- No Entry
Recruitment
- Recruitment Status:
- Recruiting ongoing
- Reason if recruiting stopped or withdrawn:
- No Entry
Recruitment Locations
- Recruitment countries:
-
- Germany
- Number of study centers:
- Multicenter study
- Recruitment location(s):
-
- University medical center Medizinische Hochschule Hannover Hannover
- University medical center Universitätsklinikum Heidelberg Heidelberg
- Medical center Leipzig Herzzentrum Leipzig
Recruitment period and number of participants
- Planned study start date:
- 2019-04-15
- Actual study start date:
- 2019-05-13
- Planned study completion date:
- No Entry
- Actual Study Completion Date:
- No Entry
- Target Sample Size:
- 20
- Final Sample Size:
- No Entry
Inclusion Criteria
- Sex:
- All
- Minimum Age:
- 18 Years
- Maximum Age:
- 75 Years
- Additional Inclusion Criteria:
- EF < 30%; Cardiac index < 2.2 l/min/m2; Informed consent; Age between 18- 75 years old; eGFR (MDRD) between 15 - 50 ml/min/1.73m²
Exclusion Criteria
Renal Replacement Therapy (RRT); Isolated Right Heart Failure, CVP ≥25 mmHg; Cardiogenic shock due to acute coronary syndrome (ACS); Restrictive Cardiomyopathy; Hypertrophic Cardiomyopathy; Heparin-Induced Thrombocytopenia (HIT); Pulmonary vascular hypertension with PCWP < 15 mm Hg; Systolic pressure less than 75 mm Hg for 30 mins; Septic Shock; Tortuous iliac arteries (Anatomical variations) OR Inability to gain access for introducer sheath or catheterization; Severe Peripheral arterial disease (PAD); Aortic diseases: Previous intravascular repair/stenting of aorta/femoral arteries, Aortic dissection chronic or acute, known aortic aneurysm, known severe calcified aorta-iliac disease or peripheral vascular disease; Descending thoracic aortic diameter < 21 mm; Aortic or mitral valve stenosis (II or greater); Known coagulopathy ; Known thrombocytopenia or platelet dysfunction; Significant blood dyscrasia, which is defined as any hematologic disorder characterized by intravascular hemolysis or associated with increased fragility of the red blood cell; Lack of patient co-operation or no informed consent; Pregnancy
Addresses
Primary Sponsor
- Address:
- Cardiobridge GmbHLotzenäcker 472379 HechingenGermany
- Telephone:
- 074711805350
- Fax:
- 0747118053515
- Contact per E-Mail:
- Contact per E-Mail
- URL:
- http://www.cardiobridge.com/
- Investigator Sponsored/Initiated Trial (IST/IIT):
- No
Contact for Scientific Queries
- Address:
- Cardiobridge GmbHKarim El BanayosyLotzenäcker 472379 HechingenGermany
- Telephone:
- 074711805350
- Fax:
- 0747118053515
- Contact per E-Mail:
- Contact per E-Mail
- URL:
- http://www.cardiobridge.com/
Contact for Public Queries
- Address:
- Cardiobridge GmbHKarim El BanayosyLotzenäcker 472379 HechingenGermany
- Telephone:
- 074711805350
- Fax:
- 0747118053515
- Contact per E-Mail:
- Contact per E-Mail
- URL:
- http://www.cardiobridge.com/
Principal Investigator
- Address:
- Cardiobridge GmbHKarim El BanayosyLotzenäcker 472379 HechingenGermany
- Telephone:
- 074711805350
- Fax:
- 0747118053515
- Contact per E-Mail:
- Contact per E-Mail
- URL:
- http://www.cardiobridge.com/
Sources of Monetary or Material Support
Commercial (pharmaceutical industry, medical engineering industry, etc.)
- Address:
- Cardiobridge GmbHLotzenäcker 472379 HechingenGermany
- Telephone:
- 074711805350
- Fax:
- 0747118053515
- Contact per E-Mail:
- Contact per E-Mail
- URL:
- http://www.cardiobridge.com/
Ethics Committee
Address Ethics Committee
- Address:
- Ethikkommission der Medizinischen Hochschule HannoverCarl-Neuberg-Str. 130625 HannoverGermany
- Telephone:
- +49-511-5323443
- Fax:
- +49-511-5325423
- Contact per E-Mail:
- Contact per E-Mail
- URL:
- No Entry
Vote of leading Ethics Committee
- Vote of leading Ethics Committee
- Date of ethics committee application:
- 2017-06-20
- Ethics committee number:
- 7551
- Vote of the Ethics Committee:
- Approved
- Date of the vote:
- 2017-09-26
Further identification numbers
- Other primary registry ID:
- No Entry
- EudraCT Number:
- No Entry
IPD - Individual Participant Data
- Do you plan to make participant-related data (IPD) available to other researchers in an anonymized form?:
- No Entry
- IPD Sharing Plan:
- No Entry
Study protocol and other study documents
- Study protocols:
- No Entry
- Study abstract:
- No Entry
- Other study documents:
- No Entry
- Background literature:
- No Entry
- Related DRKS studies:
- No Entry
Publication of study results
- Planned publication:
- No Entry
- Publikationen/Studienergebnisse:
- No Entry
- Date of first publication of study results:
- No Entry
- DRKS entry published for the first time with results:
- No Entry
Basic reporting
- Basic Reporting / Results tables:
- No Entry
- Brief summary of results:
- No Entry